Aligos Therapeutics (ALGS)
(Real Time Quote from BATS)
$0.46 USD
+0.05 (11.65%)
Updated Jul 9, 2024 03:48 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Aligos Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 136 | 126 | 191 | 244 | 118 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 8 | 14 | 6 | 2 |
Total Current Assets | 141 | 134 | 204 | 250 | 120 |
Net Property & Equipment | 3 | 5 | 6 | 8 | 9 |
Investments & Advances | 0 | 0 | 15 | 0 | 10 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 0 | 0 |
Total Assets | 152 | 147 | 235 | 265 | 147 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 5 | 3 | 3 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 17 | 16 | 25 | 17 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 9 | 8 | 8 | 0 |
Total Current Liabilities | 24 | 33 | 39 | 30 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 4 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 28 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 185 |
Total Liabilities | 59 | 43 | 51 | 45 | 211 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 578 | 503 | 487 | 395 | 1 |
Retained Earnings | -487 | -399 | -303 | -175 | -66 |
Other Equity | 1 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 92 | 104 | 185 | 220 | -65 |
Total Liabilities & Shareholder's Equity | 152 | 147 | 235 | 265 | 147 |
Total Common Equity | 92 | 104 | 185 | 220 | -65 |
Shares Outstanding | 75.10 | 42.90 | 42.60 | 36.60 | NA |
Book Value Per Share | 1.23 | 2.42 | 4.34 | 6.01 | 0.00 |
Fiscal Year End for Aligos Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 113 | 136 | 71 | 91 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 5 | 5 | 4 | 3 |
Total Current Assets | NA | 118 | 141 | 75 | 94 |
Net Property & Equipment | NA | 3 | 3 | 4 | 4 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 128 | 152 | 86 | 106 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 3 | 3 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 12 | 17 | 12 | 14 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 1 | 4 | 7 |
Total Current Liabilities | NA | 19 | 24 | 22 | 27 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 28 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 68 | 59 | 31 | 37 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 581 | 578 | 513 | 510 |
Retained Earnings | NA | -522 | -487 | -459 | -441 |
Other Equity | NA | 0 | 1 | 1 | 1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 60 | 92 | 55 | 70 |
Total Liabilities & Shareholder's Equity | NA | 128 | 152 | 86 | 106 |
Total Common Equity | 0 | 60 | 92 | 55 | 70 |
Shares Outstanding | 78.10 | 75.60 | 75.10 | 43.50 | 43.50 |
Book Value Per Share | 0.00 | 0.79 | 1.23 | 1.26 | 1.60 |